Loading...
Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia
Gilteritinib induces 2 distinct marrow responses in FLT3-mutated AML: responses with and without differentiation. Ongoing clonal hematopoiesis is ubiquitous during gilteritinib therapy and may promote genetic evolution and drug resistance.
Saved in:
| Published in: | Blood Adv |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
American Society of Hematology
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6538870/ https://ncbi.nlm.nih.gov/pubmed/31122910 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018029496 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|